Pioglitazone inhibits high glucose-induced expression of receptor for advanced glycation end products in coronary artery smooth muscle cells

Di,Bei‑Bing; Li,Hong‑Wei; Li,Wei‑Ping; Shen,Xu‑Hua; Sun,Zhi‑Jun; Wu,Xing

doi:10.3892/mmr.2014.3113

Pioglitazone inhibits high glucose-induced expression of receptor for advanced glycation end products in coronary artery smooth muscle cells

Authors:
- Bei‑Bing Di
- Hong‑Wei Li
- Wei‑Ping Li
- Xu‑Hua Shen
- Zhi‑Jun Sun
- Xing Wu
View Affiliations

Affiliations: Department of Cardiology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, P.R. China
Published online on: December 18, 2014 https://doi.org/10.3892/mmr.2014.3113
Pages: 2601-2607
Copyright: © Di et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Receptor for advanced glycation end products (RAGE) is critical in inflammatory diseases, including diabetes and atherosclerosis. The mechanism underlying the effect of peroxisome proliferator‑activated receptor γ (PPARγ) agonist pioglitazone (PIO) on RAGE expression in coronary artery smooth muscle cells (SMCs) stimulated by high glucose concentrations remains to be elucidated. In the present study, the effect and mechanism of action of PIO on RAGE expression in SMCs was investigated following treatment with high glucose concentrations. Rat coronary artery SMCs were pretreated with PIO alone, PIO and GW9662 (a PPARγ antagonist), diphenyleneiodonium (DPI; a nicotinamide adenine dinucleotide phosphate (NADPH) oxidase inhibitor) or the antioxidant pyrrolidine dithiocarbamate (PDTC; a nuclear factor‑κB (NF‑κB) inhibitor), followed by treatment with high glucose. RAGE mRNA and protein expression, reactive oxygen species (ROS) production and NF‑κB nuclear translocation were investigated. Glucose induced RAGE expression in a dose‑dependent manner, with maximal effect at a concentration of 25 mmol/l following treatment for 48 h. PIO, DPI and PDTC reduced high glucose‑induced increases in RAGE protein and mRNA expression. PIO prominently downregulated RAGE expression and inhibited high glucose‑induced increases in ROS production and NF‑κB activation (P<0.05). Pretreatment with PIO and GW9662 did not exhibit this inhibitory effect. High glucose may stimulate RAGE expression in coronary artery SMCs through NADPH oxidase‑mediated ROS generation and NF‑κB activation. PIO downregulated RAGE expression and inhibited ROS production and NF‑κB activation via PPARγ activation, which may prevent the inflammatory effect of AGE/RAGE system in diabetes.

View Figures

View References

1	Hofmann MA, Drury S, Fu C, et al: RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/calgranulin polypeptides. Cell. 97:889–901. 1999. View Article : Google Scholar : PubMed/NCBI
2	Bierhaus A and Nawroth PP: Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immuneresponses and diabetes mellitus and its complications. Diabetologia. 52:2251–2263. 2009. View Article : Google Scholar : PubMed/NCBI
3	Leclerc E, Fritz G, Vetter SW and Heizmann CW: Binding of S100 proteins to RAGE: An update. Biochim Biophys Acta. 1793:993–1007. 2009. View Article : Google Scholar : PubMed/NCBI
4	Gao X, Zhang HR, Schmidt AM and Zhang C: AGE/RAGE produces endothelial dysfunction in coronary arterioles in Type 2 diabetic mice. Am J Physiol Heart Circ Physiol. 295:H491–H498. 2008. View Article : Google Scholar : PubMed/NCBI
5	Sakaguchi T, Yan SF, Yan SD, et al: Central role of rage dependent neointimal expansion in arterial restenosis. J Clin Invest. 111:959–972. 2003. View Article : Google Scholar : PubMed/NCBI
6	Cipollone F, Iezzi A, Fazia M, et al: The receptor rage as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: Role of glycemic control. Circulation. 108:1070–1077. 2003. View Article : Google Scholar : PubMed/NCBI
7	Wang K, Zhou Z, Zhang M, et al: Peroxisome proliferator activated receptor gamma down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model. J Pharmacol Exp Ther. 317:37–43. 2006. View Article : Google Scholar
8	De Oliveira C, Colette C, Monnier L, Descomps B and Pares-Herbute N: Insulin alters nuclear factor-lambdab and peroxisome proliferator-activated receptor-gamma protein expression induced by glycated bovine serum albumin in vascular smooth-muscle cells. J Lab Clin Med. 145:1440–1450. 2005. View Article : Google Scholar
9	Li H, Chai Q, Gutterman DD and Liu Y: Elevated glucose impairs cAMP mediated dilation by reducing Kv channel activity in rat small coronary smooth muscle. Am J Physiol Heart Circ Physiol. 285:H1213–H1219. 2003.PubMed/NCBI
10	Yoon SJ, Yoon YW, Lee BK, et al: Potential role of hmg coareductase inhibitor on oxidative stress induced by advanced glycation endproducts in vascular smooth muscle cells of diabetic vasculopathy. Exp Mol Med. 41:802–811. 2009. View Article : Google Scholar : PubMed/NCBI
11	Yoon YW, Kang TS, Lee BK, et al: Pathobiological role of advanced glycation endproducts via mitogen-activated protein kinase dependent pathway in the diabetic vasculopathy. Exp Mol Med. 40:398–406. 2008. View Article : Google Scholar : PubMed/NCBI
12	San Martin A, Foncea R, Laurindo FR, et al: Nox1-based nadph oxidase-derived superoxide is required for vsmc activation by advanced glycation end-products. Free Radic Biol Med. 42:1671–1679. 2007. View Article : Google Scholar : PubMed/NCBI
13	Sakata N, Meng J and Takebayashi S: Effects of advanced glycation end products on the proliferation and fibronectin production of smooth muscle cells. J Atheroscler Thromb. 7:169–176. 2000. View Article : Google Scholar
14	Ren X, Shao H, Wei Q, Sun Z and Liu N: Advanced glycation end products enhance calcification in vascular smooth muscle cells. J Int Med Res. 37:847–854. 2009. View Article : Google Scholar : PubMed/NCBI
15	Tanikawa T, Okada Y, Tanikawa R and Tanaka Y: Advanced glycation end products induce calcification of vascular smooth muscle cells through rage/p38 mapk. J Vasc Res. 46:572–580. 2009. View Article : Google Scholar : PubMed/NCBI
16	Wei Q, Ren X, Jiang Y, Jin H, Liu N and Li J: Advanced glycation end products accelerate rat vascular calcification through RAGE/oxidative stress. BMC Cardiovasc Disord. 13:132013. View Article : Google Scholar : PubMed/NCBI
17	Hayakawa E, Yoshimoto T, Sekizawa N, Sugiyama T and Hirata Y: Overexpression of receptor for advanced glycation end products induced monocyte chemoattractant protein-1 expression in rat vasculat smooth muscle cell line. J Atheroscler Thromb. 19:13–22. 2012. View Article : Google Scholar
18	Soro-Paavonen A, Watson AM, Li J, Paavonen K, et al: Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes. 57:2461–2469. 2008. View Article : Google Scholar : PubMed/NCBI
19	Bu DX, Rai V, Shen X, et al: Activation of the ROCK1 branch of the transforming growth factor-beta pathway contributes to RAGE-dependent acceleration of atherosclerosis in diabetic ApoE-null mice. Circ Res. 106:1040–1051. 2010. View Article : Google Scholar : PubMed/NCBI
20	Ueno H, Koyama H, Shoji T, et al: Receptor for advanced glycation end-products (RAGE) regulation of adiposity and adiponectin is associated with atherogenesis in apoE-deficient mouse. Atherosclerosis. 211:431–436. 2010. View Article : Google Scholar : PubMed/NCBI
21	Li J and Schmidt AM: Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem. 272:16498–16506. 1997. View Article : Google Scholar : PubMed/NCBI
22	Yuan X1, Zhang Z, Gong K, Zhao P, Qin J and Liu N: Inhibition of reactive oxygen species/extracellular signal-regulated kinases pathway by pioglitazone attenuates advanced glycation end products-induced proliferation of vascular smooth muscle cells in rats. Biol Pharm Bull. 34:618–623. 2011. View Article : Google Scholar : PubMed/NCBI